Trial Profile

Chemotherapy free treatment with venetoclax and obinutuzumab for relapsed / refractory primary CNS lymphoma patients (VENOBI-CNS study) – A phase IB study to assess the pharmacokinetics in the cerebrospinal fluid - VENOBI-CNS

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 21 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Jan 2022 Status changed from suspended to discontinued due to low recruitment.
15 Sep 2021 Status changed from recruiting to suspended due to low recruitment.
31 Mar 2020 Planned End Date changed from 1 Dec 2023 to 1 Mar 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com